Katie S. Murray, D.O., M.S.

An expert discusses how clinicians now face the exciting challenge of selecting optimal treatments from multiple new options for BCG-unresponsive patients, opening opportunities for clinical research to determine the best sequencing and patient-specific approaches.

An expert discusses how gene therapy represents a breakthrough treatment approach for BCG-unresponsive patients, offering quarterly dosing that reduces treatment burden while showing promising response rates of 50% to 70% in real-world evidence.

An expert discusses how patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) now have several FDA-approved treatment options beyond radical cystectomy, including pembrolizumab, gene therapy and intravesical chemotherapy combinations.

An expert discusses how non-muscle invasive bladder cancer (NMIBC) creates a significant clinical and financial burden with up to 60% recurrence rates, affecting an estimated 85,000 new patients annually and requiring frequent office visits that impact quality of life for this older population.

An expert discusses how non-muscle invasive bladder cancer (NMIBC) is a localized form of urothelial cell carcinoma that primarily affects older men with smoking as the primary risk factor, requiring close follow-up due to its highly recurrent nature.